克利加巴林

克利加巴林
臨床資料
商品名（英语：Drug nomenclature）	思美宁
其他名稱	HSK16149
法律規範狀態
法律規範	中：处方药 ; 美：研究性新药（英语：Investigational New Drug）;
识别信息
CAS号	2209104-84-5
UNII	Q3MK7E8686;
化学信息
化学式	C12H19NO2
摩尔质量	209.29 g·mol−1

克利加巴林（英語：Crisugabalin，研发代号：HSK16149），商品名思美宁，是一种选择性GABA类似物，正在开发用于治疗慢性疼痛。它的治療指數比作用机制相似的普瑞巴林更广。该药物由海思科医药集团研发，于2024年5月在中国大陆获批用于治疗糖尿病性周围神经病理性疼痛^[2]^[3]，7月获批第二个适应症带状疱疹后神经痛（英语：Postherpetic neuralgia）^[4]。在美国，该药物已于2023年进入III期临床试验阶段^[5]^[6]。该药物可与食物同服或空腹服用^[7]。

克利加巴林的作用机制尚不明确^[1]。

参见

研究性镇痛药列表（英语：List of investigational analgesics）

参考来源

^ ^1.0 ^1.1 ^1.2 思美宁（苯磺酸克利加巴林胶囊）. 丁香园·用药助手. [2025-04-26].
^ Monthly Report: New Drug Approval in China, May 2024. [2025-04-26]. （原始内容存档于2024-12-09）.
^ 国家药监局批准苯磺酸克利加巴林胶囊上市. 国家药品监督管理局. 2024-05-20 [2025-04-26].
^ 海思科苯磺酸克利加巴林胶囊获批新适应症. 中国医药创新促进会. 2024-07-19 [2025-04-26].
^ Gou, Xiaoli; Yu, Xiaojuan; Bai, Dongdong; Tan, Bowei; Cao, Pingfeng; Qian, Meilin; Zheng, Xiaoxiao; Chen, Lei; Shi, Zongjun; Li, Yao; Ye, Fei; Liang, Yong; Ni, Jia. Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. 2021-03, 376 (3): 330–337. ISSN 1521-0103. PMID 33293377. doi:10.1124/jpet.120.000315 .
^ Guo, Xiaohui; Zhang, Tingting; Yuan, Geheng; Yukun, LI; Hua Ma, Jian; Hong-Mei, LI. 224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study. Diabetes. 2023, 72. doi:10.2337/db23-224-OR.
^ Wu, Qingqing; Zhu, Huijuan; Song, Rong; Zhang, Mengqi; Li, Fangqiong; Zeng, Weifang; Wang, Wei; Jia, Jingying; Yu, Chen; Liu, Yanmei. Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects. Pharmacology Research & Perspectives. 2023-06, 11 (3): e01102. PMC 10199234 . PMID 37208866. doi:10.1002/prp2.1102 .

这是一篇與药学相關的小作品。您可以通过编辑或修订扩充其内容。

[dxy-1] 1.0 ^1.1 ^1.2 思美宁（苯磺酸克利加巴林胶囊）. 丁香园·用药助手. [2025-04-26].

[2] Monthly Report: New Drug Approval in China, May 2024. [2025-04-26]. （原始内容存档于2024-12-09）.

[3] 国家药监局批准苯磺酸克利加巴林胶囊上市. 国家药品监督管理局. 2024-05-20 [2025-04-26].

[4] 海思科苯磺酸克利加巴林胶囊获批新适应症. 中国医药创新促进会. 2024-07-19 [2025-04-26].

[5] Gou, Xiaoli; Yu, Xiaojuan; Bai, Dongdong; Tan, Bowei; Cao, Pingfeng; Qian, Meilin; Zheng, Xiaoxiao; Chen, Lei; Shi, Zongjun; Li, Yao; Ye, Fei; Liang, Yong; Ni, Jia. Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. 2021-03, 376 (3): 330–337. ISSN 1521-0103. PMID 33293377. doi:10.1124/jpet.120.000315 .

[6] Guo, Xiaohui; Zhang, Tingting; Yuan, Geheng; Yukun, LI; Hua Ma, Jian; Hong-Mei, LI. 224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study. Diabetes. 2023, 72. doi:10.2337/db23-224-OR.

[7] Wu, Qingqing; Zhu, Huijuan; Song, Rong; Zhang, Mengqi; Li, Fangqiong; Zeng, Weifang; Wang, Wei; Jia, Jingying; Yu, Chen; Liu, Yanmei. Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects. Pharmacology Research & Perspectives. 2023-06, 11 (3): e01102. PMC 10199234 . PMID 37208866. doi:10.1002/prp2.1102 .

[1]

[2]

[3]

[4]

[5]

[6]

[7]